Rakha, N., El Afifi, A., Abdelallim, N., Abdallah, N. (2022). Fibroblast Growth Factor23 as a Novel Marker of Renal Impairment in Multiple Myeloma. test, 89(1), 5556-5560. doi: 10.21608/ejhm.2022.265283
Nahed Moawad Rakha; Amal Mostafa El Afifi; Nada Shawky Abdelallim; Nour El Hoda Hussein Abdallah. "Fibroblast Growth Factor23 as a Novel Marker of Renal Impairment in Multiple Myeloma". test, 89, 1, 2022, 5556-5560. doi: 10.21608/ejhm.2022.265283
Rakha, N., El Afifi, A., Abdelallim, N., Abdallah, N. (2022). 'Fibroblast Growth Factor23 as a Novel Marker of Renal Impairment in Multiple Myeloma', test, 89(1), pp. 5556-5560. doi: 10.21608/ejhm.2022.265283
Rakha, N., El Afifi, A., Abdelallim, N., Abdallah, N. Fibroblast Growth Factor23 as a Novel Marker of Renal Impairment in Multiple Myeloma. test, 2022; 89(1): 5556-5560. doi: 10.21608/ejhm.2022.265283

Fibroblast Growth Factor23 as a Novel Marker of Renal Impairment in Multiple Myeloma

The Egyptian Journal of Hospital Medicine
Article 225, Volume 89, Issue 1, October 2022, Pages 5556-5560    PDF (576.85 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2022.265283
Authors
Nahed Moawad Rakha* ; Amal Mostafa El Afifi; Nada Shawky Abdelallim; Nour El Hoda Hussein Abdallah
Clinical Hematology Unit, Internal Medicine Department, Ain shams university, Cairo Egypt
Abstract
Background: Osteoblasts, the cells that make up bone, produce and secrete fibroblast growth factor 23 (FGF23). People with chronic renal disease had a higher-than-normal levels of FGF23 in their blood.
Objective: The goal of this study was to examine FGF23's possible predictive function for renal impairment (RI) in patients with multiple myeloma (MM).
Patients and Methods: Intact FGF23 serum levels were measured in four groups of patients: 1st Group: 20 MM patients with RI either on dialysis or not; 2nd Group: 20 MM patients without RI; 3rd Group: 30 healthy individuals; 4th Group: 10 RI patients without MM.
Results In this study, we found that both MM patients with and without RI had elevated levels of FGF23 (mean=158.50 and 94.75, respectively) than in healthy individuals (mean=25.17). The difference in results between the MM and healthy individual groups was highly significant (p < 0.01). Patients with MM and RI have greater serum iFGF23 levels compared to those with MM and no RI (p < 0.05). Significant direct link exists between iFGF23 and creatinine (p < 0.01), (r=0.689). There is a strong inverse correlation between eGFR and iFGF23 in the serum (p < 0.01).
Conclusion: FGF23 levels increase significantly in MM with RI patients and are higher in MM patients with RI than those without RI. Renal impairment in MM may be diagnosed and predicted with the help of FGF23.
 
Keywords
Fibroblast Growth Factor 23; glomerular filtration rate; biomarker; Multiple Myeloma; Renal Impairment. Footnote: This abstract was presented at the 2021 annual meeting of the Society of Hematologic Oncology (SOHO).
Statistics
Article View: 132
PDF Download: 327